Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study

NCT01947803 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.

NCT NCT01947803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01947803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study
Lead sponsor
Xian-Janssen Pharmaceutical Ltd.
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2013
Completion date
March 31, 2015
Enrollment
353 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia